According to the article, Merck announced the collaboration:
Merck & Co. Inc. (NYSE:MRK) just announced another move to expand the drug’s addressable market. Merck is now collaborating with biotech company OncoSec Medical Inc. (NASDAQ:ONCS) on a phase II registration trial on melanoma patients.